

Intl. App. No.: PCT/EP98/08
Docket No. B45124

Sub C 2
5. (Amended) A composition as claimed in claim 1 [, 2 or 3] wherein the E6 protein is mutated.

Sub C 2
6. (Amended) A composition as claimed in [any of claims 1 to 5 additionally] claim 1 further comprising a histidine tag of at least 4 histidine residues.

Sub C 3
7. (Amended) A composition as claimed [herein] in claim 1 further comprising an additional HPV antigen.

A2
8. (Amended) A composition as claimed [herein where] in claim 1 wherein the immunomodulatory CpG oligonucleotide comprises a hexamer motif: purine purine cytosine guanine pyrimidine pyrimidine.

A2
9. (Amended) A composition as claimed [herein] in claim 1 wherein the immunomodulatory CpG oligonucleotide has two or more CpG motifs.

A2
10. (Amended) A composition as claimed [herein] in claim 1 wherein the CpG oligonucleotide contains a phosphorothioate inter-nucleotide linkage.

Sub B 17
11. (Amended) A composition as claimed [herein] in claim 1 wherein the CpG oligonucleotide is selected from the group consisting of:

OLIGO 1: TCC ATG ACG TTC CTG ACG TT;

OLIGO 2: TCT CCC AGC GTG CGC CAT; and

OLIGO 3: ACC GAT GAC GTC GCC GGT GAC GGC ACC ACG

A3
13. (Amended) A method of inducing an immune response in a patient to an HPV antigen comprising administering a safe and effective amount of a composition as claimed [herein] in claims 1-11 or 16.